Chronic Graft Versus Host Disease Clinical Trial
Official title:
The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
Cicatrizing conjunctivitis can be the common presentation of many ocular surface diseases as
Stevens-Johnson syndrome (SJS), mucous membrane pemphigoid (MMP), chemical burn, Sjogren
syndrome, chronic graft-versus-host disease (GVHD) and ocular trauma. Ocular dryness in
combination with symblepharon and corneal opacity in these patients could lead to the poor
visual and life quality, and less favorable prognosis of ocular reconstruction.
This study aims to prospectively evaluate the therapeutic effects of minor salivary gland
transplantation for cicatrizing conjunctivitis. The investigators evaluate the saliva-tear
productivity (functional outcome) and the survival of graft (anatomical outcome) every three
months. The investigators would also validate whether minor salivary gland transplantation is
beneficial for the participant prior to further ocular reconstruction as limbal
transplantation and corneal grafting.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Terminated |
NCT02337517 -
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Terminated |
NCT02461134 -
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
|
Phase 2 | |
| Active, not recruiting |
NCT00637689 -
Improving Outcomes Assessment in Chronic GVHD
|
||
| Not yet recruiting |
NCT06233110 -
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
|
Phase 1 | |
| Active, not recruiting |
NCT01937468 -
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 1 | |
| Completed |
NCT01380535 -
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
|
Early Phase 1 | |
| Completed |
NCT01810718 -
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 1 | |
| Terminated |
NCT01964625 -
Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
|
N/A | |
| Active, not recruiting |
NCT03790332 -
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01680965 -
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02491359 -
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT06300320 -
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
| Terminated |
NCT02701634 -
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
| Recruiting |
NCT06247150 -
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
|
N/A | |
| Active, not recruiting |
NCT04212416 -
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02959944 -
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
|
Phase 3 | |
| Completed |
NCT01954979 -
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1 | |
| Active, not recruiting |
NCT04640025 -
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
|
Phase 2 |